Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 19/20 | 0.55 |
| ▸ | ITGAV | P06756 | 13/20 | 0.54 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.46 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504467 | 0.89 | ITGAV (0.44) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL6499934 | 0.89 | ITGB3 (0.61) | ITGB3ITGA2BITGAV | |
| SCHEMBL6503828 | 0.87 | ITGB3 (0.49) | ITGB3ITGA2BITGAV | |
| SCHEMBL6506046 | 0.86 | ITGB3 (0.69) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL6496630 | 0.85 | ITGB3 (0.59) | ITGB3ITGA2BITGAV | |
| SCHEMBL6499146 | 0.84 | ITGB3 (0.51) | ITGB3ITGA2BITGAV | |
| SCHEMBL6498897 | 0.84 | ITGB3 (0.47) | ITGB3ITGA2BITGAV | |
| SCHEMBL6500032 | 0.84 | ITGB3 (0.44) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL6506996 | 0.83 | ITGB3 (0.58) | ITGB3ITGA2BITGAV | |
| SCHEMBL6500800 | 0.83 | ITGB3 (0.64) | ITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | claimed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | claimed |
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | disclosed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | ITGAV, ITGB3, ITGA4 | ITGB3 2/4885ITGA2B 23/4885ITGAV 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.